Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008, 152(1):47-51 | DOI: 10.5507/bp.2008.007

EXPRESSION OF MULTIDRUG RESISTANCE-RELATED PROTEIN (MRP-1), LUNG RESISTANCE-RELATED PROTEIN (LRP) AND TOPOISOMERASE-II (TOPO-II) IN WILMS’ TUMOR: IMMUNOHISTOCHEMICAL STUDY USING TMA METHODOLOGY

Eduard Fridmana, Jozef Skardab, Jonatan H Pinthusc, Jonathan Ramonc, Yoran Mord
a Departments of Pathology and Urology, Chaim Sheba Medical Center
b Sackler School of Medicine, Tel-Aviv University, Israel
c Department of Pathology, Faculty of Medicine and Dentistry, Palacky University, 775 15 Olomouc, Czech Republic
d Department of Surgery, McMaster University, Hamilton, Ontario, Canada

Aims: MRP-1, LRP and TOPO-II are all associated with protection of the cells from the adverse effects of various chemotherapeutics. The aim of this study was to measure the expression of these proteins in Wilms' tumor (WT).

Materials and Methods: TMA block was constructed from 14 samples of WT's and from xenografts derived from them. Sections of the TMA were used for immunostaining against MRP-1, LRP and TOPO-IIa.

Results: All normal kidneys expressed MRP-1 but were either weakly or negatively stained for LRP and TOPO-IIa. In WT samples, MRP-1 was universally expressed, exclusively in the tubular component, while there was no expression of LRP and TOPO-IIa showed heterogeneous distribution. The xenografts varied in their MRP-1 and TOPO-IIa expression and exhibited weak/negative staining of LRP.

Conclusions: This study shows that although all the proteins evaluated, had different expression patterns in the tumor samples, the most prominent changes in expression were found for MRP-1. The exact clinical implications of these changes in expression and their relevance to the resistance of these tumors to chemotherapy requires further investigation. The finding of different expression profiles for the multidrug resistance proteins in the original WT's and their xenografts suggests that the results of animal cancer models may be difficult to interpret.

Keywords: MRP (multidrug resistance related protein), LRP (lung resistance protein), TOPO-II (topoisomerase II), Nephroblastoma,

Received: February 25, 2008; Accepted: April 10, 2008; Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fridman, E., Skarda, J., Pinthus, J.H., Ramon, J., & Mor, Y. (2008). EXPRESSION OF MULTIDRUG RESISTANCE-RELATED PROTEIN (MRP-1), LUNG RESISTANCE-RELATED PROTEIN (LRP) AND TOPOISOMERASE-II (TOPO-II) IN WILMS’ TUMOR: IMMUNOHISTOCHEMICAL STUDY USING TMA METHODOLOGY. Biomedical papers, 152(1), 47-51. doi: 10.5507/bp.2008.007
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dekel Y, Frede T, Kugel V, Neumann G, Rassweiler J, Koren R. Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma. Oncol Rep 2005; 14:271-4. Go to PubMed...
    2. Eff erth T, Bode ME, Schulten HG, Thelen P, Granzen B, Beniers AJ, Mertens R, Gefeller O, Ringert RH, Jakse G, Fuzesi L. Diff erential expression of the lung resistance-related protein/major vault protein in the histological compartments of nephroblastomas. Int J Oncol 2001; 19:163-8. Go to original source...
    3. Eff erth T, Thelen P, Schulten HG, Bode ME, Granzen B, Beniers AJ, Mertens R, Ringert RH, Gefeller O, Jakse G, Fuzesi L. Diff erential expression of the multidrug resistance-related protein MRP1 in the histological compartments of nephroblastomas. Int J Onco 2001; 19:367-71. Go to original source...
    4. Gamelin E, Mertins SD, Regis JT, Mickley L, Abati A, Worrell RA, Linehan WM, Bates SE. Intrinsic drug resistance in primary and metastatic renal cell carcinoma. J Urol 1999; 62:217-24. Go to original source... Go to PubMed...
    5. Gillet JP, Eff erth T, Steinbach D, Hamels J, de Longueville F, Bertholet V, Remacle J. Microarray-based detection of multidrug resistance in human tumor cells by expression profi ling of ATPbinding cassette transporter genes. Cancer Res 2004; 64:8987-93. Go to original source... Go to PubMed...
    6. Granzen B, Eff erth T, Keller U, Beniers AJ, Mertens R, Jakse G, Fuzesi L. Diff erential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors. Anticancer Res 2001; 21:771-6. Go to PubMed...
    7. Kim WJ, Kakehi Y, Kinoshita H, Arao S, Fukumoto M, Yoshida O. Expression patterns of multidrug-resistance (MDR1), multidrug resistance associated protein (MRP), glutathiione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney. J Urol 1996; 156:506-11. Go to original source... Go to PubMed...
    8. Kong CZ, Zeng Y, Wu XX, Li JO, Zhu YY, Chen Y. Increased expression of lung resistance-related protein in lower grade urothelial carcinoma of the renal pelvis and ureter. Int J Urol 2004; 11:721- 7. Go to original source... Go to PubMed...
    9. Koren R, Kugel V, Dekel Y, Weissman Y, Livne PM, Gal R. Human DNA topoisomerase-IIalpha expression as a prognostic factor for transitional cell carcinoma of the urinary bladder. BJU Int 2003; 91:489-92. Go to original source... Go to PubMed...
    10. Laurencot CM, Scheff er GL, Scheper RJ, Shoemaker RH. Increased LRP Mrna expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int J Cancer 1997; 72:1021-6. Go to original source... Go to PubMed...
    11. Leslie EM, Deeley RG, Cole SPC. Multidrug resistance proteins: role of Pglycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defence. Toxicology and Applied Pharmacology 2005; 204:216- 37. Go to original source... Go to PubMed...
    12. Nooter K, Westerman AM, Flens MJ, Zaman GJ, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995; 1:1301-10. Go to original source...
    13. Shergill IS, Rao AR, Anjum FH, Arya M, Patel HRH, Mundy AR. Tissue microarrays and their relevance to the urologist. J Urol 2006; 175:19-26. Go to original source... Go to PubMed...
    14. Sugawara I, Akiyama S, Scheper RJ, Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 1997; 112:23-31. Go to original source... Go to PubMed...
    15. Sugimura J, Yang XJ, Tretiakova MS, Takahashi M, Kort EJ, Fulton B, Fujioka T, Vogelzang NJ, The BT. Gene expression profi ling of mesoblastic nephroma and Wilms' tumors comparison of clinical implications. Urology 2004; 64:362-8. Go to original source... Go to PubMed...
    16. Takahashi M, Yang XJ, Lavery TT, Furge KA, Williams BO, Tretiakova M, Montag A, Vogelzang NJ, Re GG, Garvin AJ, Soderhall S, Kagawa S, Hazel-Martin D, Nordenskjold A, Teh BT. Gene expression profi lling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res 2002; 15:6598- 605.
    17. Tretiakova M, Turkyilmaz M, Grushko T, Kocherginsky M, Rubin C, The B, Yang XJ. Topoisomerase II alpha in Wilms tumors: gene alterations and immunoexpression. J Clin Pathol 2006; 59:1272- 7. Go to original source... Go to PubMed...
    18. Volm M, Kastel M, Mattern J, Eff erth T. Expression of resistance factors (Pglycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 1993; 71:3981-7. Go to original source... Go to PubMed...
    19. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J. Revised International Society of Paediatric Oncology (SIOP) working classifi cation of renal tumors of childhood. Med Pediatr Oncol 2002; 38:79-82. Go to original source... Go to PubMed...
    20. Yu DS, Ma CP, Chang SY. Establishment and characterization of renal cell carcinoma cell lines with multidrug resistance. Urol Res 2000; 28:86-92. Go to original source... Go to PubMed...
    21. Pinthus JH, Fridman E, Dekel B, Goldberg I, Kaufman-Francis K, Eshhar Z, Harmelin A, Rechavi G, Mor O, Ramon J, Mor Y. ErbB2 is a tumor-associated antigen and a suitable therapeutic target in Wilms tumor. J. Urol. 2004; 172:1644-1648. Go to original source... Go to PubMed...

    Return to the content